Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports

BACKGROUND: Three checkpoint inhibitor drugs have been approved by the US Food and Drug Administration for use in specific types of cancers. While the results are promising, severe immunotherapy-related adverse events (irAEs) have been reported. OBJECTIVES: To conduct a systematic review of case rep...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdel-Wahab, Noha, Shah, Mohsin, Suarez-Almazor, Maria E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966895/
https://www.ncbi.nlm.nih.gov/pubmed/27472273
http://dx.doi.org/10.1371/journal.pone.0160221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966895/
https://www.ncbi.nlm.nih.gov/pubmed/27472273
http://dx.doi.org/10.1371/journal.pone.0160221

Ejemplares similares